myk-224
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 21, 2022 (NCT05304533)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07248839 | Phase 1 | Dec 15, 2025 | Bristol-Myers Squibb |
| NCT07226817 | Phase 1 | Nov 12, 2025 | Bristol-Myers Squibb |
| NCT06577259 | Phase 1 | Sep 3, 2024 | Bristol-Myers Squibb |
| NCT06476821 | Phase 1 | Jun 27, 2024 | Bristol-Myers Squibb |
| NCT06122779 | Phase 2 | Nov 7, 2023 | Bristol-Myers Squibb |
| NCT05686096 | Phase 1 | Jan 16, 2023 | Bristol-Myers Squibb |
| NCT05556343 | Phase 2 | Sep 30, 2022 | Bristol-Myers Squibb |
| NCT05405543 | Phase 1 | Jul 12, 2022 | Bristol-Myers Squibb |
| NCT05304533 | Phase 1 | Apr 21, 2022 | Bristol-Myers Squibb |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 9 | 9 | 2 | 2022 |
1 organizations
Page 1 / 1